These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23204035)

  • 1. Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe.
    Ciaranello AL; Perez F; Engelsmann B; Walensky RP; Mushavi A; Rusibamayila A; Keatinge J; Park JE; Maruva M; Cerda R; Wood R; Dabis F; Freedberg KA
    Clin Infect Dis; 2013 Feb; 56(3):430-46. PubMed ID: 23204035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers.
    Ciaranello AL; Perez F; Maruva M; Chu J; Engelsmann B; Keatinge J; Walensky RP; Mushavi A; Mugwagwa R; Dabis F; Freedberg KA;
    PLoS One; 2011; 6(6):e20224. PubMed ID: 21655097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing infant HIV diagnosis with additional screening at immunization clinics in three sub-Saharan African settings: a cost-effectiveness analysis.
    Dunning L; Gandhi AR; Penazzato M; Soeteman DI; Revill P; Frank S; Phillips A; Dugdale C; Abrams E; Weinstein MC; Newell ML; Collins IJ; Doherty M; Vojnov L; Fassinou Ekouévi P; Myer L; Mushavi A; Freedberg KA; Ciaranello AL
    J Int AIDS Soc; 2021 Jan; 24(1):e25651. PubMed ID: 33474817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis.
    Ciaranello AL; Perez F; Keatinge J; Park JE; Engelsmann B; Maruva M; Walensky RP; Dabis F; Chu J; Rusibamayila A; Mushavi A; Freedberg KA
    PLoS Med; 2012 Jan; 9(1):e1001156. PubMed ID: 22253579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Point-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysis.
    Ciaranello AL; Myer L; Kelly K; Christensen S; Daskilewicz K; Doherty K; Bekker LG; Hou T; Wood R; Francke JA; Wools-Kaloustian K; Freedberg KA; Walensky RP
    PLoS One; 2015; 10(3):e0117751. PubMed ID: 25756498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and Cost Drivers of Providing Option B+ Services to Mother-Baby Pairs for PMTCT of HIV in Health Centre IV Facilities in Jinja District, Uganda.
    Mukose AD; Kebede S; Muhumuza C; Makumbi F; Komakech H; Bayiga E; Busobozi D; Musinguzi J; Kuznik A; Stegman P; Forsythe S; Kagaayi J
    Biomed Res Int; 2020; 2020():2875864. PubMed ID: 32550228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health outcomes and cost impact of the new WHO 2013 guidelines on prevention of mother-to-child transmission of HIV in Zambia.
    Ishikawa N; Shimbo T; Miyano S; Sikazwe I; Mwango A; Ghidinelli MN; Syakantu G
    PLoS One; 2014; 9(3):e90991. PubMed ID: 24604067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Option B+ for the prevention of mother-to-child transmission of HIV infection in developing countries: a review of published cost-effectiveness analyses.
    Karnon J; Orji N
    Health Policy Plan; 2016 Oct; 31(8):1133-41. PubMed ID: 27016949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV.
    O'Brien L; Shaffer N; Sangrujee N; Abimbola TO
    Bull World Health Organ; 2014 Mar; 92(3):162-70. PubMed ID: 24700975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries.
    Sweat MD; O'Reilly KR; Schmid GP; Denison J; de Zoysa I
    AIDS; 2004 Aug; 18(12):1661-71. PubMed ID: 15280777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of integrating postpartum antiretroviral therapy and infant care into maternal & child health services in South Africa.
    Dugdale CM; Phillips TK; Myer L; Hyle EP; Brittain K; Freedberg KA; Cunnama L; Walensky RP; Zerbe A; Weinstein MC; Abrams EJ; Ciaranello AL;
    PLoS One; 2019; 14(11):e0225104. PubMed ID: 31730630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of option B plus for prevention of mother-to-child transmission of HIV in resource-limited countries: evidence from Kumasi, Ghana.
    VanDeusen A; Paintsil E; Agyarko-Poku T; Long EF
    BMC Infect Dis; 2015 Mar; 15():130. PubMed ID: 25887574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
    ; de Vincenzi I
    Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother-to-child transmission of HIV: implications for resource-limited countries in sub-Saharan Africa.
    Ngambi PG; Kalungia AC; Law MR; Kalemeera F; Truter I; Godman B; Munkombwe D
    Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):459-467. PubMed ID: 28770641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol for the evaluation of the population-level impact of Zimbabwe's prevention of mother-to-child HIV transmission program option B+: a community based serial cross-sectional study.
    Koyuncu A; Dufour MK; McCoy SI; Bautista-Arredondo S; Buzdugan R; Watadzaushe C; Dirawo J; Mushavi A; Mahomva A; Cowan F; Padian N
    BMC Pregnancy Childbirth; 2019 Jan; 19(1):15. PubMed ID: 30621615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost and cost-effectiveness of transitioning to universal initiation of lifelong antiretroviral therapy for all HIV-positive pregnant and breastfeeding women in Swaziland.
    Cunnama L; Abrams EJ; Myer L; Gachuhi A; Dlamini N; Hlophe T; Kikuvi J; Langwenya N; Mthethwa S; Mudonhi D; Nhlabatsi B; Nuwagaba-Biribonwoha H; Okello V; Sahabo R; Zerbe A; Sinanovic E
    Trop Med Int Health; 2018 Sep; 23(9):950-959. PubMed ID: 29956426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIV.
    Gopalappa C; Stover J; Shaffer N; Mahy M
    AIDS; 2014 Jan; 28 Suppl 1():S5-14. PubMed ID: 24468947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative cost-effectiveness of Option B+ for prevention of mother-to-child transmission of HIV in Malawi.
    Tweya H; Keiser O; Haas AD; Tenthani L; Phiri S; Egger M; Estill J
    AIDS; 2016 Mar; 30(6):953-62. PubMed ID: 26691682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings.
    Dugdale CM; Ufio O; Alba C; Permar SR; Stranix-Chibanda L; Cunningham CK; Fouda GG; Myer L; Weinstein MC; Leroy V; McFarland EJ; Freedberg KA; Ciaranello AL
    J Int AIDS Soc; 2023 Jan; 26(1):e26052. PubMed ID: 36604316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.